Please assess the completion status of the following clinical trial:

Trial Title: Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients 18-50 years of age, who have signed an informed consent form.~2. Clinical evidence of asthma~3. Steroid naïve asthmatic patients~4. FEV1 at Screening Visit is \>70 % of the predicted value and at least 2.0 L.~5. Body Mass Index between 18 and 35.~6. Sensitivity to AMP at Screening Visit.~7. FENO levels \>25 ppb at the Screening Visit~Exclusion Criteria:~1. Having received an investigational product within 2 months of Screening Visit.~2. Inability to comply with study procedures or with study treatment intake.~3. Any significant lung disease which is considered by the investigator to be clinically significant.~4. Patients who suffer from Chronic Obstructive Pulmonary Disease (COPD)~5. Previous or current smokers who have a smoking history greater than 5 pack years.~6. Patients with any uncontrolled disease that might, in the judgment of the investigator, place the patients at undue risk or potentially compromise the results or interpretation of the study.~7. Patients with QTc \>450msec at the Screening Visit.~8. Patients with serum potassium \<3.5 mEq/L or \>6 mEq/L.~9. Intolerance/hypersensitivity or any contra-indication to treatment with beta2-agonists and/or inhaled corticosteroids.~10. Patients who have a history of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.~11. Patients who have undergone major surgery in the previous 3 months.~12. Patients who have had an exacerbation of asthma, requiring treatment with oral steroids during the last month prior to Screening Visit.~13. Patients treated with slow-release corticosteroids 2 months prior to Screening Visit.~14. Patients currently treated with anti-IgE Antibodies.~15. Patients who have had a respiratory tract infection within 4-weeks prior to Screening Visit.~16. Females not willing to use effective contraceptive measures such as oral contraceptive or intra-uterine device (IUD).~17. Females who are pregnant, lactating or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pMDI
- Low dose (Type: EXPERIMENTAL): BDP/formoterol pMDI low dose
- High dose (Type: EXPERIMENTAL): BDP/Formoterol pMDI high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).